RxDoctor Payments Data

Barry Uhl, MD

Radiation Oncology · la Mesa, CANPI 1811936693

Payments from drug & device makers

$8,648in general payments, 2019–2025

Across 373 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$852
  • Merck$623
  • Incyte Corporation$460
  • AstraZeneca$450
  • Eisai Inc.$335
  • Johnson & Johnson$334
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis42$852
Merck26$623
Incyte Corporation22$460
AstraZeneca(2 entities)20$450
Eisai Inc.16$335
Johnson & Johnson(2 entities)16$334
Takeda Pharmaceuticals U.S.A., Inc.13$300
Regeneron Healthcare Solutions, Inc.10$275
Sanofi11$270
Genentech USA, Inc.10$247
Astellas Pharma US Inc11$237
Pfizer9$195
Daiichi Sankyo Inc.11$194
Sirtex Medical Inc1$189
Rigel Pharmaceuticals, Inc.6$171
AbbVie6$171
Bayer8$165
Puma Biotechnology, Inc.8$148
Pharmacyclics LLC, An Abbvie Company5$147
Pharmaessentia USA Corporation4$137
Lilly USA, LLC8$135
Beigene USA, Inc.5$131
Karyopharm Therapeutics Inc.4$126
Tersera Therapeutics LLC4$118
Genmab U.S., Inc.4$113
Coherus Oncology, Inc.4$105
Sumitomo Pharma America, Inc.6$101
Blueprint Medicines Corporation4$100
Deciphera Pharmaceuticals Inc.3$89
Sobi, Inc4$89
Seagen Inc.3$80
Stemline Therapeutics Inc.3$68
Taiho Oncology, Inc.3$67
Amgen3$66
EMD Serono, Inc.3$63
Siemens Medical Solutions USA, Inc.2$61
Boehringer Ingelheim2$56
Alnylam Pharmaceuticals Inc.3$54
Tempus AI, Inc2$53
Springworks Therapeutics, Inc.2$53
Accord Healthcare, Inc.2$51
Exelixis Inc.2$50
Pharmacosmos Therapeutics Inc.2$49
Novo Nordisk2$47
Elekta, Inc.1$46
Recordati_rare_diseases_inc.2$46
Bristol Myers Squibb2$45
Servier Pharmaceuticals LLC2$44
Progenics Pharmaceuticals, Inc.2$43
Legend Biotech USA Inc.2$41
Iovance Biotherapeutics, Inc.2$38
Morphosys, US Inc.2$38
AVEO Pharmaceuticals, Inc.2$34
Dendreon Pharmaceuticals LLC1$34
GE HealthCare1$31
Beone Medicines USA, Inc.1$28
Adaptive Biotechnologies Corporation1$26
Octapharma USA, Inc.1$25
EUSA Pharma (US) LLC1$24
Immunogen, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,648 in reported general payments places this provider in the 80th percentile of 627 radiation oncology providers in California.

See all radiation oncology providers in California

Medicare billing

Part B allowed, 2024
$186,269
Medicare patients
228
Services billed
1,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl56$403

Paid to pharmacies, not to this prescriber.

Other radiation oncology in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →